In an interview about the efficacy of COVID-19 vaccines, Richard Marlink, the director of Rutgers Global Health Institute, responds to public opinion about the differences among vaccines that are authorized or in the pipeline for use in the United States. The following is an excerpt from the story published by ROI-NJ: When the news that Johnson & Johnson had completed Phase 3 of its clinical trial and that its one-shot vaccine would soon be available finally was released Friday morning, there was unbridled excitement. It would be a game-changer, many said. To read the full story.
- Overdose deaths from fentanyl combined with stimulants increased 50-fold since 2010.
- Sober socializing, a growing movement in New Jersey.
- Register for the NJ ACTS Biostatisics, Epidemiolgy, Research Design Workshop Series on 10/19 for
- Op-Ed: Stand up for cancer patients, innovation and access to life-saving therapies
- New NJACTS Publication